Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
Date: 14 Feb 2018
Type: FSRH Clinical Guidance and Clinical Statements
This statement provides guidance on contraceptive options for women taking (or whose male partners are taking) known teratogenic drugs or drugs with potential teratogenic effects.
FSRH guidance advises that women of reproductive age who are taking known teratogenic drugs or drugs with potential teratogenic effects should always be advised to use highly effective contraception both during treatment and for the recommended timeframe after discontinuation to avoid unintended pregnancy.
Detailed information regarding teratogenic drugs or drugs with potential teratogenic effects is available from the UK teratogenic information service (UKTIS) website.
The full statement can be downloaded and saved at the link below.
